RecruitingPhase 1Phase 2NCT06840119

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers

Sponsor

Immunocore Ltd

Enrollment

600 participants

Start Date

Jan 10, 2024

Study Type

INTERVENTIONAL

Conditions

Cancer HLA-A*02:01-positive

Summary

This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Antiangiogenic Agent, Chemotherapy drug, and others for people with cancer and hla-a*02:01-positive. The study is currently recruiting participants at 13 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIMC-R117C

IV infusion

DRUGChemotherapy drug

IV infusion

DRUGChemotherapy drug

oral

DRUGKinase inhibitor

oral

DRUGAntiangiogenic Agent

IV infusion

DRUGMonoclonal antibody

IV infusion

Locations(13)

St Vincent's Hospital

Darlinghurst, Sydney, Australia

Peter MacCallum Cancer Centre

Melbourne, Australia

Institut Jules Bordet

Anderlecht, Belgium

Universitair Ziekenhuis Gent

Ghent, Belgium

UZ Leuven

Leuven, Belgium

Universitaetsklinikum Heidelberg

Heidelberg, Germany

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Roma, Italy

nstituto Clinico Humanitas

Rozzano, Italy

Antoni van Leeuwenhoek

Amsterdam, Netherlands

Hospital HM Nou Delfos

Barcelona, Spain

VHIO, Vall d'Hebron University Hospital

Barcelona, Spain

Centro Integral Oncologico Clara Campal

Madrid, Spain

Hospital Universitario Fundacion Jimenez Diaz

Madrid, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06840119

Related Trials

Resilience Mobile App for Teens and Young Adults With Cancer

NCT058429021 location

Rare Tumors and Cancer Predisposition in Individuals and Families

NCT053507612 locations

Evolution of Insomnia During the First Year in Patients Newly Diagnosed With Cancer

NCT072804161 location

Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data

NCT07743021

Impact of Gonadotoxic Therapies on Fertility

NCT058850481 location